Every moment counts when treating a patient with a heart attack.
At least 50% of heart-attack deaths occur before the patient reaches the hospital.1Dudas et al, Trends in Out-of-Hospital Deaths Due to Coronary Heart Disease in Sweden (1991 to 2006). Circulation. 2011;123:46-52
Disaggpro™ (zalunfiban) gives the gift of time.2Disaggpro is an investigational drug product that has not been approved by the U.S. Food and Drug Administration for safety and effectiveness. CeleBrate, the global, multicenter Phase 3 clinical trial of Disaggpro has finished enrollment.
CeleBrate, the global, multicenter Phase 3 clinical trial of Disaggpro has finished enrollment.
About Disaggpro
Disaggpro is a next-generation investigational GPIIb/IIIa platelet inhibitor that was specifically designed for pre-hospital treatment of heart attacks and is injected subcutaneously (under the skin). It provides rapid, high-grade, limited-duration platelet inhibition within minutes.
Disaggpro reaches maximal effect within 15 minutes and has a half-life of about two hours,3Bentur OS, et al. Assessing the Pharmacodynamics of RUC-4 (Zalunfiban), a Novel αIIbβ3 Antagonist, Using VerifyNow Assays in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Treated with Aspirin and Ticagrelor [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). which may reduce the risk of bleeding and avoid interfering with later patient treatment.
Symptoms of heart attack begin
Patient is administered Disaggpro
Rapid onset of action
About Us
Each year, 800,000 people in the United States have an acute myocardial infarction (AMI), or heart attack. We founded CeleCor Therapeutics to improve the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact.
